The global pharmaceutical continuous manufacturing market size reached US$ 1.2 Billion in 2022. Looking forward, the analyst expects the market to reach US$ 2.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.6% during 2023-2028.
Pharmaceutical continuous manufacturing refers to an end-to-end medication production approach that enhances the quality and consistency of various novel drugs and vaccines with minimal capital investments. As compared to batch processing, it operates in a continuous flow, is easier to scale, offers greater control to manufacturers and a higher level of automation, and eliminates physical intervention. Apart from this, pharmaceutical continuous manufacturing aids in minimizing the medicine formulation duration, risk of human errors, monitoring the production procedures, and improving the product quality to harmonize with the regulatory guidelines. Consequently, the technique is extensively utilized by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (API) and medicines. At present, it is available in integrated, semi-continuous, and control types.
2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2023-2028?
3. What are the key factors driving the global pharmaceutical continuous manufacturing market?
4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market?
5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
9. What are the key regions in the global pharmaceutical continuous manufacturing market?
10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?
Pharmaceutical continuous manufacturing refers to an end-to-end medication production approach that enhances the quality and consistency of various novel drugs and vaccines with minimal capital investments. As compared to batch processing, it operates in a continuous flow, is easier to scale, offers greater control to manufacturers and a higher level of automation, and eliminates physical intervention. Apart from this, pharmaceutical continuous manufacturing aids in minimizing the medicine formulation duration, risk of human errors, monitoring the production procedures, and improving the product quality to harmonize with the regulatory guidelines. Consequently, the technique is extensively utilized by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (API) and medicines. At present, it is available in integrated, semi-continuous, and control types.
Pharmaceutical Continuous Manufacturing Market Trends:
One of the primary factors currently driving the market is the increasing demand for effective medicine production systems for composing various effective biologics at a lower cost. This can be further attributed to the rising drug shortages and the growing prevalence of several chronic ailments across the globe. Additionally, the rising health concerns, especially during the coronavirus disease (COVID-19) pandemic outbreak, have prompted pharmaceutical companies to use continuous manufacturing techniques to compose novel vaccines, which is acting as another growth-inducing factor. In line with this, significant technological advancements, such as rapid automation in the pharmaceutical manufacturing methodology and the large-scale integration of artificial intelligence (AI) solutions, are contributing to the market growth. Other factors, such as significant improvements in the pharmaceutical sector, ongoing research and development (R&D) activities, and the escalating awareness about the availability of food and drug administration (FDA) approved medicines, are creating a positive outlook for the market.Key Market Segmentation
The report provides an analysis of the key trends in each sub-segment of the market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on therapeutics type, formulation, application and end user.Breakup by Therapeutics Type:
- Large Molecules
- Small Molecules
Breakup by Formulation:
- Solid Formulation
- Liquid and Semi-solid Formulation
Breakup by Application:
- Final Drug Product Manufacturing
- API Manufacturing
Breakup by End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.Key Questions Answered in This Report
1. How big is the global pharmaceutical continuous manufacturing market?2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2023-2028?
3. What are the key factors driving the global pharmaceutical continuous manufacturing market?
4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market?
5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
9. What are the key regions in the global pharmaceutical continuous manufacturing market?
10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Pharmaceutical Continuous Manufacturing Market
6 Market Breakup by Therapeutics Type
7 Market Breakup by Formulation
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Baker Perkins
- Coperion GmbH (Hillenbrand Inc.)
- Eli Lilly
- Company
- GEA Group Aktiengesellschaft
- Glatt GmbH
- Korsch AG
- Novartis AG
- Siemens
- SK biotek
- Thermo Fisher Scientific Inc. and Viatris Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | October 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1.2 Billion |
| Forecasted Market Value ( USD | $ 2.3 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
